Shinobi Therapeutics Strengthens Leadership with Key Appointments
Portfolio - People | Dec 18, 2024 | Fast Track Initiative Inc
Shinobi Therapeutics, part of Fast Track Initiative Inc.'s investment portfolio, has announced the appointment of two new leaders to its team: Dr. Luis Borges as Chief Scientific Officer and Dr. Steven Katz as Chief Medical Officer. Dr. Borges, an expert in immunology and oncology, brings a wealth of experience in moving therapies from the discovery stage to clinical development. Dr. Katz, renowned for his expertise in clinical development, will oversee the acceleration of Shinobi's pipeline into clinical trials. These strategic hires aim to fortify Shinobi's efforts in pioneering innovative cell therapies, specifically iPSC-T and NK cell products, which target GPC3+ solid tumors and autoimmune diseases. The expansion of the leadership team highlights Shinobi's commitment to addressing significant unmet medical needs through cutting-edge scientific advancements.
Sectors
- Biotechnology
- Healthcare
Geography
- Global – Shinobi Therapeutics, being a pioneer in cell therapy, operates in a space that has global implications and outreach.
Industry
- Biotechnology – Shinobi Therapeutics is involved in biotechnology, specifically in developing cell therapies for oncology and autoimmune diseases.
- Healthcare – The appointments of a Chief Scientific Officer and a Chief Medical Officer highlight the company's focus on healthcare innovation.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Shinobi Therapeutics | Target company | Company | A portfolio company of Fast Track Initiative Inc. specializing in cell therapies for autoimmune diseases and oncology. |
| Fast Track Initiative Inc. | Private Equity Firm | Company | A private equity firm with a portfolio that includes Shinobi Therapeutics. |
| Luis Borges, PhD | Chief Scientific Officer | Person | An expert in immunology and oncology, bringing experience in advancing therapies from discovery to clinical trials. |
| Steven Katz, MD | Chief Medical Officer | Person | A clinical development leader responsible for advancing Shinobi's therapeutic pipeline. |